AMEX:CRMD

Stock Analysis Report

Executive Summary

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • CorMedix is covered by less than 3 analysts.

Share Price & News

How has CorMedix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.6%

CRMD

1.2%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

152.6%

CRMD

-8.4%

US Pharmaceuticals

0.7%

US Market

CRMD outperformed the Pharmaceuticals industry which returned -8.4% over the past year.

CRMD outperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

CRMDIndustryMarket
7 Day4.6%1.2%-0.6%
30 Day5.9%1.8%2.9%
90 Day8.2%-4.3%1.3%
1 Year152.6%152.6%-6.2%-8.4%2.9%0.7%
3 Year-39.1%-39.1%12.6%4.7%44.6%35.2%
5 Year-15.9%-15.9%22.9%9.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is CorMedix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CorMedix undervalued based on future cash flows and its price relative to the stock market?

12.15x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for CorMedix to establish if it is available at moderate discount.

Unable to calculate intrinsic value for CorMedix to establish if it is available at substantial discount.


Price Based on Earnings

CorMedix is loss making, we can't compare its value to the US Pharmaceuticals industry average.

CorMedix is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CorMedix, we can't assess if its growth is good value.


Price Based on Value of Assets

CorMedix is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is CorMedix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-92.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CorMedix's revenue is expected to grow significantly at over 20% yearly.

CorMedix is not considered high growth as it is expected to be loss making for the next 1-3 years.

CorMedix's revenue growth is expected to exceed the United States of America market average.

Unable to compare CorMedix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare CorMedix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CorMedix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CorMedix performed over the past 5 years?

-12.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CorMedix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare CorMedix's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CorMedix's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CorMedix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CorMedix has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CorMedix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CorMedix's financial position?


Financial Position Analysis

CorMedix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CorMedix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CorMedix's level of debt (40.9%) compared to net worth is high (greater than 40%).

Unable to establish if CorMedix's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

CorMedix has sufficient cash runway for 1.3 years based on current free cash flow.

CorMedix has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 4.5% each year.


Next Steps

Dividend

What is CorMedix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CorMedix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CorMedix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CorMedix has not reported any payouts.

Unable to verify if CorMedix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CorMedix has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CorMedix's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Khoso Baluch (61yo)

2.9yrs

Tenure

US$586,841

Compensation

Mr. Khoso Baluch has been the Chief Executive Officer of CorMedix, Inc. since October 3, 2016. Mr. Baluch served as Senior Vice President and President Europe, Middle East & Africa EMEA at UCB, SA or UCB,  ...


CEO Compensation Analysis

Khoso's remuneration is lower than average for companies of similar size in United States of America.

Khoso's compensation has increased whilst company is loss making.


Management Age and Tenure

2.0yrs

Average Tenure

62yo

Average Age

The tenure for the CorMedix management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

62yo

Average Age

The average tenure for the CorMedix board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by CorMedix individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$8,18019 Aug 19
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max PriceUS$8.18
BuyUS$48,36016 Aug 19
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares6,000
Max PriceUS$8.06
BuyUS$50,34416 Aug 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,147
Max PriceUS$8.19
BuyUS$75,11117 May 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares11,144
Max PriceUS$6.74
BuyUS$93501 Apr 19
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares100
Max PriceUS$9.35
BuyUS$18,87527 Mar 19
Khoso Baluch
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares2,500
Max PriceUS$7.55
BuyUS$38,65027 Mar 19
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares5,000
Max PriceUS$7.73
BuyUS$25,35025 Mar 19
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares3,000
Max PriceUS$8.45
BuyUS$33,00022 Mar 19
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares4,000
Max PriceUS$8.25
BuyUS$69,97220 Mar 19
Janet Dillione
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,400
Max PriceUS$8.33
BuyUS$23,50021 Dec 18
Wade Capital Corporation, Money Purchase Plan
EntityCompany
Shares4,000
Max PriceUS$5.88
BuyUS$124,41021 Dec 18
Mehmood Khan
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceUS$6.22
BuyUS$73,30017 Dec 18
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max PriceUS$7.33
BuyUS$363,15030 Nov 18
John Armstrong
EntityIndividual
Role
Chief Technology Officer
Head of Human Resources & Executive VP of Technical Operations
Shares50,000
Max PriceUS$7.26
BuyUS$30,49527 Nov 18
Khoso Baluch
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares5,000
Max PriceUS$6.40
BuyUS$29,21327 Nov 18
Robert Cook
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceUS$5.84
BuyUS$64,79527 Nov 18
Myron Kaplan
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max PriceUS$6.48

Ownership Breakdown


Management Team

  • Jack Armstrong (75yo)

    Head of Human Resources & Executive VP of Technical Operations

    • Tenure: 2.5yrs
    • Compensation: US$369.27k
  • Bob Cook (63yo)

    Chief Financial Officer

    • Tenure: 2.6yrs
    • Compensation: US$434.18k
  • Paul Chew

    Consultant Advisor Chief Medical Officer

    • Tenure: 1.3yrs
  • Liz Masson (40yo)

    Executive VP & Head of Clinical Operations

    • Tenure: 1.5yrs
    • Compensation: US$364.48k
  • Khoso Baluch (61yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$586.84k
  • Phoebe Mounts

    Executive VP & General Counsel

    • Tenure: 0.3yrs

Board Members

  • Myron Kaplan (73yo)

    Chairman of the Board

    • Tenure: 2.1yrs
    • Compensation: US$70.88k
  • Janet Dillione (60yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$54.42k
  • Steve Lefkowitz (63yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$67.46k
  • C. Webb

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Mehmood Khan (60yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$53.57k
  • Bruce Polsky (65yo)

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Michael Allon

    Chairman of Scientific Advisor Board

    • Tenure: 0yrs
  • Paul Flyer

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Bruce Reidenberg

    Member of Scientific Advisor Board

    • Tenure: 0yrs
  • Khoso Baluch (61yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$586.84k

Company Information

CorMedix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CorMedix, Inc.
  • Ticker: CRMD
  • Exchange: AMEX
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$200.181m
  • Shares outstanding: 23.80m
  • Website: https://www.cormedix.com

Number of Employees


Location

  • CorMedix, Inc.
  • 400 Connell Drive
  • Suite 5000
  • Berkeley Heights
  • New Jersey
  • 7922
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRMDAMEX (NYSE MKT LLC)YesClass A Common StockUSUSDMay 2010
19KADB (Deutsche Boerse AG)YesClass A Common StockDEEURMay 2010

Biography

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:10
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.